Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Kamaraj R
A significant section of the Substances and Cosmetics Act (Government of India) is Schedule E1, which contains a list of toxic drugs with animal, plant, and mineral origins that must be consumed under medical supervision. The world’s oldest medical system, Ayurveda, has a list of medications included in category E1 that have been in use for a very long time. This review details the anti-cancer properties of fifteen poisonous ayurvedic medicines derived from plants that are listed under the 1940 Drugs and Cosmetics Act [1-15]. The data was gathered from a variety of reliable sources, compiled, and summarised. extracts from plants, Mammary carcinoma, neuroblastoma, non-small cell lung carcinoma, lymphocytic leukaemia, colorectal adenocarcinoma, Ehrlich ascites carcinoma, prostate adenocarcinoma, glioblastoma asterocytoma, and other malignancies have been successfully treated with formulations, phytoconstituents, and other preparations of these drugs. They work by a number of different methods, including as upregulating Bax and downregulating Bcl2, causing cell cycle arrest during the S and G2/M phases, inhibiting vascular endothelial growth factors, and inhibiting Akt/mTOR signalling, among others. These herbs are used in several traditional ayurveda remedies, which have been reported to have positive effects. These medications have been discussed as adjuvant and alternative treatment agents in the context of current cancer care. According to the findings, these medications may one day be used to treat cancers urgently.